Deciphering the role of ADAM15 vs. ADAM17 in fibroblast function: Mechanobiology vs. Proteolysis
解读 ADAM15 与 ADAM17 在成纤维细胞功能中的作用:机械生物学与蛋白水解
基本信息
- 批准号:RGPIN-2022-03408
- 负责人:
- 金额:$ 2.84万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Discovery Grants Program - Individual
- 财政年份:2022
- 资助国家:加拿大
- 起止时间:2022-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Fibroblasts (FBs) are the main cells for synthesis and homeostasis of the extracellular matrix (ECM) in various tissues. FBs respond to external stimuli and adjust their function (proliferation, migration, activation) accordingly. Excess FB activation leads to overproduction of ECM (scar/fibrosis), while the inverse results in structural instability. Disintegrin and metalloproteinase-15 (ADAM15) and ADAM17 are two highly expressed ADAMs in FBs, and are (incorrectly) assumed to have similar functions, though recent findings suggest otherwise. Our prior research in cardiovascular disease models has revealed the dire need to understand the unique mechanistic function of each ADAM, and the fundamental processes by which they regulate FB function and ECM remodeling. ADAM15 is unique as the only ADAM to cleave an ECM protein, whereas ADAM17 is the most versatile sheddase with >80 substrates. ADAMs have the ability to proteolytically process membrane-bound proteins and to also interact with integrins (through their disintegrin domain), but it is yet to be determined which mechanism takes priority, and if this is specific to an ADAM or to the nature of the stimulus. We hypothesize that in FBs, ADAM15 predominantly functions through its C-terminus-mediated signaling, and by interacting with integrins and activating the associated intracellular signaling; whereas the function of ADAM17 is primarily through proteolytic shedding of membrane-bound proteins (growth factors, cytokines) enhancing their bioavailability and their downstream pathways. Over the next 5 years, we will investigate the comparative function of ADAM15 and ADAM17 in the function of FBs in ECM production and homeostasis in response to pharmacological versus mechanical stimuli. We will use a primary FB culture system, and will knockdown ADAM15 or ADAM17 using siRNA (scrambled siRNA will be used as control in parallel). Subsequently, FBs will be treated with pharmacological stimuli (Angiotensin II or Phenylephrine) or subjected to mechanical stress (rhythmic or static stretching, FlexCell5000 system). FB activity (synthesis of ECM proteins, contractility), proliferation, migration, and survival will be investigated in control, ADAM15- and ADAM17-deficient FBs (±stimulus). Detailed molecular and mechanistic analyses will be performed to compare and contrast the role of these two ADAMs in agonist-induced versus mechanical activation of FBs and the overall ECM remodeling. My lab has extensive experience in studying ECM remodeling and FB functions. We have all the equipment and expertise necessary to conduct the described experiments. These experiments will reveal novel mechanism of action for ADAM15 and -17 in FB function and ECM remodeling, and will create new knowledge in cell physiology and natural sciences by determining the proteolytic and mechano-sensory functions of these ADAMs in FBs, which would be beneficial in the fields of cell- and mechano-biology.
Fibroblasts (FBs) are the main cells for synthesis and homeostasis of the extracellular matrix (ECM) in various tissues. FBs respond to external stimuli and adjust their function (proliferation, migration, activation) accordingly. Excess FB activation leads to overproduction of ECM (scar/fibrosis), while the inverse results in structural instability. Disintegrin and metalloproteinase-15 (ADAM15) and ADAM17 are two highly expressed ADAMs in FBs, and are (incorrectly) assumed to have similar functions, though recent findings suggest otherwise. Our prior research in cardiovascular disease models has revealed the dire need to understand the unique mechanistic function of each ADAM, and the fundamental processes by which they regulate FB function and ECM remodeling. ADAM15 is unique as the only ADAM to cleave an ECM protein, whereas ADAM17 is the most versatile sheddase with >80 substrates. ADAMs have the ability to proteolytically process membrane-bound proteins and to also interact with integrins (through their disintegrin domain), but it is yet to be determined which mechanism takes priority, and if this is specific to an ADAM or to the nature of the stimulus. We hypothesize that in FBs, ADAM15 predominantly functions through its C-terminus-mediated signaling, and by interacting with integrins and activating the associated intracellular signaling; whereas the function of ADAM17 is primarily through proteolytic shedding of membrane-bound proteins (growth factors, cytokines) enhancing their bioavailability and their downstream pathways. Over the next 5 years, we will investigate the comparative function of ADAM15 and ADAM17 in the function of FBs in ECM production and homeostasis in response to pharmacological versus mechanical stimuli. We will use a primary FB culture system, and will knockdown ADAM15 or ADAM17 using siRNA (scrambled siRNA will be used as control in parallel). Subsequently, FBs will be treated with pharmacological stimuli (Angiotensin II or Phenylephrine) or subjected to mechanical stress (rhythmic or static stretching, FlexCell5000 system). FB activity (synthesis of ECM proteins, contractility), proliferation, migration, and survival will be investigated in control, ADAM15- and ADAM17-deficient FBs (±stimulus). Detailed molecular and mechanistic analyses will be performed to compare and contrast the role of these two ADAMs in agonist-induced versus mechanical activation of FBs and the overall ECM remodeling. My lab has extensive experience in studying ECM remodeling and FB functions. We have all the equipment and expertise necessary to conduct the described experiments. These experiments will reveal novel mechanism of action for ADAM15 and -17 in FB function and ECM remodeling, and will create new knowledge in cell physiology and natural sciences by determining the proteolytic and mechano-sensory functions of these ADAMs in FBs, which would be beneficial in the fields of cell- and mechano-biology.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kassiri, Zamaneh其他文献
Tissue inhibitor of metalloproteinases (TIMPs) in heart failure
- DOI:
10.1007/s10741-011-9266-y - 发表时间:
2012-09-01 - 期刊:
- 影响因子:4.6
- 作者:
Moore, Linn;Fan, Dong;Kassiri, Zamaneh - 通讯作者:
Kassiri, Zamaneh
Diverse origins and activation of fibroblasts in cardiac fibrosis
- DOI:
10.1016/j.cellsig.2020.109869 - 发表时间:
2021-02-01 - 期刊:
- 影响因子:4.8
- 作者:
Aujla, Preetinder K.;Kassiri, Zamaneh - 通讯作者:
Kassiri, Zamaneh
ADAM (a Disintegrin and Metalloproteinase) 15 Deficiency Exacerbates Ang II (Angiotensin II)-Induced Aortic Remodeling Leading to Abdominal Aortic Aneurysm
- DOI:
10.1161/atvbaha.120.314600 - 发表时间:
2020-08-01 - 期刊:
- 影响因子:8.7
- 作者:
Jana, Sayantan;Chute, Michael;Kassiri, Zamaneh - 通讯作者:
Kassiri, Zamaneh
Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm
- DOI:
10.1161/circresaha.118.313181 - 发表时间:
2018-07-20 - 期刊:
- 影响因子:20.1
- 作者:
Shen, Mengcheng;Hu, Mei;Kassiri, Zamaneh - 通讯作者:
Kassiri, Zamaneh
ADAMs family and relatives in cardiovascular physiology and pathology
- DOI:
10.1016/j.yjmcc.2015.10.031 - 发表时间:
2016-04-01 - 期刊:
- 影响因子:5
- 作者:
Zhang, Pu;Shen, Mengcheng;Kassiri, Zamaneh - 通讯作者:
Kassiri, Zamaneh
Kassiri, Zamaneh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
- 批准号:82372275
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
- 批准号:82371070
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
相似海外基金
Role of ADAM15 in cardiac remodeling and heart failure: Discovery of its novel myocardial substrates
ADAM15 在心脏重塑和心力衰竭中的作用:其新型心肌底物的发现
- 批准号:
355099 - 财政年份:2016
- 资助金额:
$ 2.84万 - 项目类别:
Operating Grants
The role of the disintegrin metalloproteinase ADAM15 in the apoptosis resistance of synovial fibroblasts in rheumatoid arthritis
解整合素金属蛋白酶ADAM15在类风湿性关节炎滑膜成纤维细胞凋亡抵抗中的作用
- 批准号:
252699675 - 财政年份:2014
- 资助金额:
$ 2.84万 - 项目类别:
Research Grants
The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis
ADAM15 在前列腺肿瘤浸润和转移中的作用
- 批准号:
8096777 - 财政年份:2010
- 资助金额:
$ 2.84万 - 项目类别:
The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis
ADAM15 在前列腺肿瘤浸润和转移中的作用
- 批准号:
8256675 - 财政年份:2010
- 资助金额:
$ 2.84万 - 项目类别:
The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis
ADAM15 在前列腺肿瘤浸润和转移中的作用
- 批准号:
8658029 - 财政年份:2010
- 资助金额:
$ 2.84万 - 项目类别:
The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis
ADAM15 在前列腺肿瘤浸润和转移中的作用
- 批准号:
8460156 - 财政年份:2010
- 资助金额:
$ 2.84万 - 项目类别:
The Role of ADAM15 in sTie2 shedding in Ischemic Angiogenesis
ADAM15 在缺血性血管生成中 sTie2 脱落中的作用
- 批准号:
7751014 - 财政年份:2009
- 资助金额:
$ 2.84万 - 项目类别:
Novel Roles for ADAM15 in Acute Lung Injury
ADAM15 在急性肺损伤中的新作用
- 批准号:
7185955 - 财政年份:2007
- 资助金额:
$ 2.84万 - 项目类别:
Novel Roles for ADAM15 in Acute Lung Injury
ADAM15 在急性肺损伤中的新作用
- 批准号:
7544492 - 财政年份:2007
- 资助金额:
$ 2.84万 - 项目类别:
Novel Roles for ADAM15 in Acute Lung Injury
ADAM15 在急性肺损伤中的新作用
- 批准号:
7339840 - 财政年份:2007
- 资助金额:
$ 2.84万 - 项目类别:














{{item.name}}会员




